Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 2/20 | 0.54 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21165344 | 0.89 | MPO (0.57) | MPOSCN8ATAAR1ATML3MBTL1 | |
| SCHEMBL26358055 | 0.89 | ACHE (0.53) | MPOSCN8ATAAR1ATML3MBTL1 | |
| SCHEMBL3360187 | 0.84 | MAOB (0.54) | MPOSCN8ATAAR1ATML3MBTL1 | |
| SCHEMBL11957878 | 0.83 | MPO (0.55) | MPOSCN8ATAAR1ATML3MBTL1 | |
| SCHEMBL2720282 | 0.83 | MPO (0.55) | MPOSCN8ATAAR1ATML3MBTL1 | |
| SCHEMBL30753812 | 0.83 | MPO (0.55) | MPOSCN8ATAAR1ATML3MBTL1 | |
| SCHEMBL184150 | 0.83 | LMNA (0.61) | — | |
| SCHEMBL14612436 | 0.82 | TAAR1 (0.54) | MPOSCN8ATAAR1IDO1AGXT | |
| SCHEMBL28353482 | 0.82 | MPO (0.58) | MPOSCN8ATAAR1ATML3MBTL1 | |
| SCHEMBL30573214 | 0.82 | MPO (0.58) | MPOSCN8ATAAR1ATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) | 2023-09-28 | — | — | US | disclosed |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CA) | 2023-09-28 | — | — | US | disclosed |
| US-20200246365-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CA) | 2020-08-06 | — | — | US | disclosed |
| WO-2019046931-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2019-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246365-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPASE | RAN, RANBP1, GDI2 | MPO 3469/4885SCN8A 1676/4885TAAR1 4769/4885 |
| US-20230302030-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS INHIBITORS OF RAN GTPase | RAN, RANBP1, GDI2 | MPO 3469/4885SCN8A 1676/4885TAAR1 4769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.